IP Library Granted Patent US 10,208,086
Granted Patent B2
US 10,208,086 · App. 14/357,512 · Granted Feb 19, 2019

Cyclin A1-targeted T-cell immunotherapy for cancer

Inventors: Philip Greenberg (Mercer Island, WA); Sebastian Ochsenreither (Berlin, DE)
Assignee: Fred Hutchinson Cancer Research Center
C07K7/08A61K39/0011C07K7/06C07K14/4738C12N9/12A61K38/00A61K2039/5154A61K2039/5158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,208,086
App. No.
14/357,512
Granted
Feb 19, 2019
Kind
B2
Abstract

Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.

Claims (21)

1. An isolated human cyclin A1 (CCNA1)-specific T cell comprising at least one recombinant expression vector encoding a T-cell receptor polypeptide that specifically binds in a human class I HLA-restricted manner to a CCNA1 polypeptide epitope of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, or 9 amino acids comprising the amino acid sequence set forth in SEQ ID NO:1, 3, 4, 5, 6, or 8.

2. A method for treating a condition characterized by CCNA1 overexpression in cells of a subject, comprising adoptively transferring to the subject an effective amount of the CCNA1-specific T cell of claim 1 .

3. The isolated human CCNA1-specific T cell of claim 1 wherein the polypeptide epitope is a polypeptide of general formula:

N-X-C,  [I]

wherein:

(a) N-X-C is a polypeptide of no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or 9 amino acids in which X is an amino acid sequence that is selected from:

[SEQ ID NO: 1]

CCNA1(120-131) VDTGTLKSDLHF,

[SEQ ID NO: 3]

CCNA1(227-235) FLDRFLSCM,

[SEQ ID NO: 4]

CCNA1(253-261) ASKYEEIYP,

[SEQ ID NO: 5]

CCNA1(118-127) YEVDTGTLKS,

[SEQ ID NO: 6]

CCNA1(167-175) YAEEIYQYL,

and

[SEQ IN NO: 8]

CCNA1(341-351) SLIAAAAFCLA,

(b) N is the amino terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids, and

(c) C is the carboxy terminus of the peptide and consists of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acids that are independently selected from natural amino acids and non-natural amino acids.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Aug 4, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060722/0441 →
MERGER AND CHANGE OF NAME Recorded Jun 9, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060329/0793 →
CONFIRMATORY LICENSE Recorded Dec 1, 2016
From: FRED HUTCHINSON CANCER RESEARCH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040782/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2015
From: GREENBERG, PHILIP; OCHSENREITHER, SEBASTIAN
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 035051/0584 →
Continuity (2)
Provisional Application 61558953 · Nov 11, 2011
Related Publication 20140322253A1 · Oct 30, 2014
Cited By (1)
US 12,570,712